certolizumab pegol in the treatment of spondyloarthritis
Clicks: 190
ID: 170296
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
190 views
21 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #14 of 28 articles by views in Ìnformacìjnì tehnologìï v osvìtì
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Spondyloarthropaties (SpA) are a second common group of inflammatory rheumatic diseases after systemic connective tissue diseases. They are a frequent cause of disability. Tumor necrosis factor α (TNF-α) plays a crucial role in the initiation and continuation of chronic inflammation in SpA patients. Therefore, in case of high disease activity, despite treatment with non-steroidal anti-inflammatory drugs and/or synthetic disease modifying antirheumatic drugs, treatment with biologics is very efficacious. Certolizumab pegol is a one of the TNF inhibitors, with proven efficacy in the treatment of active SpA. This article summarizes basic data on certolizumab pegol, and results of clinical trials applied for the drug registration for the use in the management of patients with active SpA.
| Reference Key |
korkosz2014rheumatologycertolizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Mariusz Korkosz |
| Journal | Ìnformacìjnì tehnologìï v osvìtì |
| Year | 2014 |
| DOI |
10.5114/reum.2014.44706
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.